Abbreviations adenylate cyclase activating p o l y p e p t i d e -(~~~i~) have not previously been reported. W e investigated the influence of PACAP, vasoactive intestinal polypeptide (68% homology with PACAP) and the B-adrenergic receptor agonist isoproterenol on contractile function and coronary vascular tone in isolated piglet hearts (1 to 5 d of age). Paced (180 beatslmin) isovolumically beating hearts underwent retrograde aortic perfusion a t constant coronary flow (approximately 3 mL. min-' . g-') with an erythrocyte-enriched PACAP, pituitary adenylate cyclase activating polypeptide VIP, vasoactive intestinal polypeptide ISP, isoproterenol IBMX, isobutylmethylxanthine dP/dt,,, maximum rate of change of systolic pressure with respect to time (+), positive (-), negative (hematocrit 15 to 20%)~solution ( 3 7 "~) . ~g o n i s t s were injected into the aortic root of hearts, and the positive (+) and negative (-) changes in maximum rate of change of systolic pressure with respect to time (dP/dtma,) and in PACAP is a newly discovered neuropcptide isolated from the coronary perfusion pressure (that reflected alterations in ovine hypothalamus (1). PACAP is present in two forms: one vascular tone) were measured. PACAP (n = 8,O.l and 0.5 with 27 and the other with 38 N-terminal amino acid residues nmol) increased (+) dP/dt,, from 944 + 59 to 1519 f 206 (2). PACAP has a 68% sequence homology with VIP and appears mm ~g / s and from 867 2 40 to 2010 +: 226 mm ~g / s ( p to be more potent than VIP in stimulating adenylate cyclase in < 0.05); increased (-1 dpldt,, from 11 14 41 to 14-39 + pituitary cells (2). PACAP also has been shown to increase cAMP 9 5 mm ~g and from 999 f 37 to 1668 + 145 mm H~/ S levels in the human neuroblastoma cell line NB-OK (3), the rat ( p < 0.05); and decreased perfusion pressure from 61.4 2 pancreatic acinar cell line AR 4-25 (4), and rat liver cell mem-3.1 to 48.9 2 2.3 mm 1 1~ and from 60.5 + 2.4 to 43.9 branes ( 5 ) . Moreover, high affinity binding sites for PACAP have 2.3 mm H~ (p < 0.05), respectively. comparison, vase-been identified in several organ systems, including the rat lung active intestinal polypeptide (n = 6, 0.1 and 0.5 nmol) (6) and h m a n brain (7). increased (+) dP/dtmn, from 767 +. 53 to 806 + 37 mm Hg/ The ~h~s i o l o g i c role of PACAP has not been elucidated, and from 829 2 94 to 942 8 5 mm ~g /~ (NS); increased although it has been suggested that this peptide may be involved (-) dp/dtma, from 883 2 73 to 926 45 ,,,,,, ~g /~ and in the regulation of vascular smooth muscle tone, in addition to from 923 + 8 2 to 1054 f 78 mm Hg/s (NS); and decreased its presumed role as a hypothalamic, hypophysiotropic hormone perfusion pressure from 57.9 + 4.9 to 50.0 +. 3.6 mm H~ (8 VIP, have been demonstrated in the myocardium and coronary duced positive inotropic, luisitropic, and coronary vasodil-arteries of several adult species (12). The present study, therefore, effects in piglet which may make a was undertaken to investigate the effects of PACAP on contractile promising cardiOtOnic agent for the treatment function and coronary vascular tone using neonatal pig hearts.
PACAP, pituitary adenylate cyclase activating polypeptide VIP, vasoactive intestinal polypeptide ISP, isoproterenol IBMX, isobutylmethylxanthine dP/dt,,, maximum rate of change of systolic pressure with respect to time (+), positive (-), negative (hematocrit 15 to 20%)~solution ( 3 7 "~) . ~g o n i s t s were injected into the aortic root of hearts, and the positive (+) and negative (-) changes in maximum rate of change of systolic pressure with respect to time (dP/dtma,) and in PACAP is a newly discovered neuropcptide isolated from the coronary perfusion pressure (that reflected alterations in ovine hypothalamus (1). PACAP is present in two forms: one vascular tone) were measured. PACAP (n = 8,O.l and 0.5 with 27 and the other with 38 N-terminal amino acid residues nmol) increased (+) dP/dt,, from 944 + 59 to 1519 f 206 (2) . PACAP has a 68% sequence homology with VIP and appears mm ~g / s and from 867 2 40 to 2010 +: 226 mm ~g / s ( p to be more potent than VIP in stimulating adenylate cyclase in < 0.05); increased (-1 dpldt,, from 11 14 41 to 14-39 + pituitary cells (2) . PACAP also has been shown to increase cAMP 9 5 mm ~g and from 999 f 37 to 1668 + 145 mm H~/ S levels in the human neuroblastoma cell line NB-OK (3), the rat ( p < 0.05); and decreased perfusion pressure from 61.4 2 pancreatic acinar cell line AR 4-25 (4) , and rat liver cell mem-3.1 to 48.9 2 2.3 mm 1 1~ and from 60.5 + 2.4 to 43.9 branes ( 5 ) . Moreover, high affinity binding sites for PACAP have 2.3 mm H~ (p < 0.05), respectively. comparison, vase-been identified in several organ systems, including the rat lung active intestinal polypeptide (n = 6, 0.1 and 0.5 nmol) (6) and h m a n brain (7) . increased (+) dP/dtmn, from 767 +. 53 to 806 + 37 mm Hg/ The ~h~s i o l o g i c role of PACAP has not been elucidated, and from 829 2 94 to 942 8 5 mm ~g /~ (NS); increased although it has been suggested that this peptide may be involved (-) dp/dtma, from 883 2 73 to 926 45 ,,,,,, ~g /~ and in the regulation of vascular smooth muscle tone, in addition to from 923 + 8 2 to 1054 f 78 mm Hg/s (NS); and decreased its presumed role as a hypothalamic, hypophysiotropic hormone perfusion pressure from 57.9 + 4.9 to 50.0 +. 3.6 mm H~ (8) . Although binding sites for PACAP have been identified on and from 59.0 4.3 to 44.6 + 3.8 mm H~, respectively ( p large blood vessels, little is known about the biological effects of < 0.05). Isoproterenol (n = 5, 0.1 and 0.5 nmol) increased PACAP in vascular beds of intact organs (9) . Recently, Minkes (+) dp1dtma, from 793 51 to 1343 + 75 mm ~g /~ ( p = ef (10) VIP, have been demonstrated in the myocardium and coronary duced positive inotropic, luisitropic, and coronary vasodil-arteries of several adult species (12) . The present study, therefore, effects in piglet which may make a was undertaken to investigate the effects of PACAP on contractile promising cardiOtOnic agent for the treatment function and coronary vascular tone using neonatal pig hearts. tropic and coronary vasodilatory effects (13) . Additionally, we studied PACAP in immature hearts because clinically a combination of inotropic support and afterload reduction through systemic vasodilatation frequently is beneficial in the treatment of neonates with myocardial contractile dysfunction.
MATERIALS AND METHODS
Preparation of erythrocytes andperfitsate. The perfusate (37°C) consisted of a crystalloid solution containing insulin (200 pU/ mL) and the following salts (in mM): NaCI, 118; KCI, 4.7; MgSO,, 2.4; KH2P04, 1.2; NaHCO,, 25; CaC12, 2.4; glucose 5.5 mM; and 2% BSA (BSA, Cohn Fraction V, U.S. Biochemical Corp., Cleveland, OH). Out-dated saline-washed human erythrocytes (tested negative for hepatitis B and human immunodeficiency virus) were then suspended in this solution (hematocrit 15 to 20%) to provide physiologic oxygen delivery and buffering capacity for these large hearts (12.0 + 0.9 g). Using this isolated heart preparation, we have previously demonstrated that enrichment of a crystalloid perfusate with either human or pig erythrocytes results in similar levels of contractile function for piglet hearts (14) . Therefore, in these experiments, banked human erythrocytes were used because of their ease of availability. The pH of the final solution was adjusted to 7.4-7.45 by titration with 1 N NaOH. The lactate concentration of the final solution was 2 to 4 mM.
Preparation of isolated hearts. Pigs, 1 to 5 d of age, were used for these studies. Isolated isovolumically beating hearts were prepared as described previously (13) (14) (15) . Briefly, piglets were anesthetized with sodium pentobarbital (25 mg/kg intraperitoneal), anticoagulated with heparin sodium (1000 U/kg i.v.), and mechanically ventilated via a tracheostomy. After a sternotomy, the hearts were excised rapidly and immediately placed in icecold Krebs-Henseleit solution.
Using the modified Langendorff system described previously (1 3-1 5) and depicted in Figure 1 , hearts underwent retrograde aortic perfusion with the crystalloid solution for approximately 5 min to flush the coronary arteries of debris and then were perfused with the erythrocyte-enriched solution. The enhanced oxygen carrying capacity, provided by the erythrocytes, ensured that coronary flow rates could be kept near the physiologic range (1 6) without compromising contractile performance. Furthermore, coronary vascular tone would be maintained, and thus coronary vascular responsiveness could be studied during the experiment. Hence, responses to agonists were investigated without the necessity and additional complexity of using agents to predilate or precontract the coronary vasculature. Such agents also might adversely affect contractile function.
Hearts were allowed to equilibrate for approximately 15 min while being perfused at constant coronary perfusion pressure. After equilibration, hearts then underwent nonrecirculating perfusion at constant coronary flow (2.7 + 0.3 mL.min-'g.-l wet heart weight). In each experiment, the flow rate was chosen to produce a coronary perfusion pressure of approximately 60 mm Hg, which is the in vivo aortic diastolic pressure measured in neonatal pigs (17) . Perfusing hearts at constant coronary flow followed us to study responses to agonists without impairing oxygen delivery, which may have adversely affected contractile function. In this preparation, coronary venous return flows from the right atrium to the right ventricle and then is pumped into the pulmonary artery, which is cannulated with a nonrestrictive (3-mm diameter) tube. Thus, the right ventricle pumps only against atmospheric pressure. The right atrial pressure is therefore low and has a minimal effect on coronary perfusion pressure. We have confirmed this result by measuring right atrial pressure using a 4-French catheter that was inserted into the right atrium via the inferior vena cava. Typically during the experiment, mean right atrial pressure was found to be 1 to 2 mm Hg. Thus, changes in coronary perfusion pressure reflected alterations in 
bubble trap ( B ) , and heating condenser ( I t ) .
Before entering the aorta, the perfusate passed through a constant-flow system containing a bubble trap ( B ) , calibrated pump ( P ) , which maintained the coronary flow at the desired constant value, a pulsatile flow damping chamber (It'), and a heating condenser (H). Coronary perfusion was switched from constant perfusion pressure to constant flow using an adjustable clamp (C).
Myocardial temperature was kept at 37°C by enclosing the heart in a heated water jacket. Left ventricular isovolumic pressure was monitored by a pressure transducer ( T I ) attached to a fluid-filled balloon catheter (BC) in the left ventricular chamber. Coronary perfusion pressure was monitored with a pressure transducer (T2) attached to a side port above the heart. Bolus injections of agonists were administered through an injection port (I) just above the aortic cannula. Coronary venous return egressed from the pulmonary artery cannula (CF). Coronary venous return was collected separately and not returned to the reservoir (R). vascular tone because right atrial pressure was low and coronary flow was held constant.
Left ventricular contractile function was assessed by isovolumic pressure generation and the dP/dt,,,, which were monitored via a 5 French fluid-filled balloon catheter in the ventricular chamber. Both (+) and (-) dP/dt,,, were determined, allowing an assessment of left ventricular inotropy and relaxation.
The left ventricular end-diastolic pressure was set at approximately 5 mm Hg, which is physiologic for a neonate, by adjusting the volume of fluid in the balloon. Once the end-diastolic pressure was set, the volume of fluid in the balloon was not changed. Therefore, changes in end-diastolic pressure reflected alterations in left ventricular compliance because coronary flow was held constant. Hearts were paced via the right ventricle at 180 beats/ min. The arterial perfusate oxygen content was maintained at approximately 7.5 to 8.0 vol % (hematocrit approximately 15% and Po2 approximately 250 to 300 mm Hg) by passing a mixture of 95% 02:5% C 0 2 through the perfusate in the Langendorff column.
Preparation of solutions. PACAP (Peptide Laboratories, Tulane University School of Medicine, New Orleans, LA) and VIP (Peninsula Laboratories Inc., Belmont, CA) were dissolved in 0.9% sodium chloride. The homogeneity of the peptides was assessed by thin-layer chromatography and analytical reversephase, HPLC. The purity of the peptides was 97% or greater. Isoproterenol HCI (Winthrop Pharmaceutical, NY) was diluted
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with saline (1: 10) before use. Propranolol HCl(1 mg/mL) (Smith & Nephew) was used directly from the vial.
E.~perimcntal protocols. The first part of this study was designed to test the cardiac effects of PACAP in eight piglet hearts. PACAP, 0.1 and 0.5 nmol, was injected as a bolus over approximately 1 s into the aortic root of each heart. These doses of PACAP were chosen so dP/dt,,, and vascular tone would return to near baseline levels on washout of the hormone. Similar doses of PACAP also have been shown to evoke vasoactive effects in the pulmonary and systemic (hindquarter) vascular beds of cats (10) . In four of the experiments, the 0.1-nmol dose of PACAP was administered first, followed by the 0.5-nmol dose. In the remaining four experiments, the order of administration was reversed. PACAP was administered only after dP/dt,,, and coronary perfusion pressure had returned to near baseline values and had stabilized. The effects of PACAP on (+) and (-) dP/ dt,,, (in m m Hg/s) and coronary perfusion pressure (in m m Hg) were then determined.
As a comparison, the effects of ISP, 0.1 and 0.5 nmol, on (+) and (-) dP/dt,,, and coronary perfusion pressure were studied in five hearts.
The second part of this study compared the effects of PACAP with VIP. In six additional hearts, VIP, 0.1 and 0.5 nmol, was studied in a method similar to that for PACAP. The changes in (+) and (-) dP/dt,,, and coronary perfusion pressure were then compared with the corresponding changes in these parameters obtained with PACAP. In another four hearts. VIP (0.1 nmol) was administered, followed by a dose of PACAP (0.1 nmol). PACAP was given approximately 30 s after VIP, when perfusion pressure had reached its nadir as a consequence of VIP. The same dose of PACAP was then administered approximately 10 min later. In each case, the effect of these agents on (+) dP/dt,,, was determined. These experiments were performed to determine whether VIP might diminish the effect of PACAP on inotropy.
The third part of this study assessed whether the inotropic effect of PACAP could be potentiated by phosphodiesterase inhibition. An augmentation of PACAP's effect on (+) dP/dt,,, by phosphodiesterase inhibition would support the premise that PACAP's inotropic action is mediated by an increase in CAMP. In the present study, we used the nonspecific phosphodiesterase inhibitor IBMX to study this effect because we have previously demonstrated that IBMX increases CAMP levels in isolated piglet myocytes (1 3). Thus, in four experiments, PACAP (0.1 nmol) was given, and its effect on (+) dP/dt,,, was determined. IBMX was then infused into the aortic root at a rate of 50 to 150 pg/ min, which produced a n approximately 12% increase in (+) dP/ dt,,,. The hearts were then rechallenged with the same dose of PACAP, and the influence of IBMX on the inotropic response of PACAP was determined.
Data analj,sis. The results are presented as means + SEM.
Analysis of variance or analysis of variance with repeated measures was used to analyze differences in the response to PACAP, VIP, and ISP. The least significant difference test was used to analyze differences among means. Differences among means were considered to be significant when p < 0.05.
RESULTS
Injllicnce (fP,,t CZ4P on cotltractilc fiinction a n d coronarjV pclrfirsion prcssurc. PACAP produced a positive inotropic and lusitropic effect, as manifested by an increase in (+) dP/dt,,, ( Fig.  2A) and (-) dP/dt,,, ( 0.05). PACAP also produced coronary vasodilatation as reflected by a decrease in coronary perfusion pressure (Fig. 3) . PACAP decreased perfusion pressure from 6 1.4 +-3.1 t o 48. contrast, in the four hearts in which the 0. I-nmol dose of PACAP was administered first, the increase in (+) dP/dt,,, for the 0.1-nmol dose was 79 1 + 26 1 mm Hg/s. However, when the 0.1-nmol dose was given first, the 0. I-nmol dose did not significantly diminish the response to the 0.5-nmol dose. These results demonstrate that a large dose of PACAP can attenuate the inotropic response to a lower dose administered later.
In four additional experiments, hearts were also treated with propranolol(100 nmol) before the administration of PACAP to determine whether the effects of PACAP were altered by @-adrenergic receptor blockade. This dose of propranolol was found to abolish, for example, the inotropic effect of 0. I nmol of ISP (see below). Pretreatment with propranolol, however, had no significant effect on the inotropic response with PACAP.
Inflltence of ISP on contractilejirnction atld coronury pcrjirsion pressure. The effects of ISP on (+) dP/dt,,,, (-) dP/dt,,,, and coronary perfusion pressure are also shown in Figures 211, 2B and 3, respectively. ISP increased (+) dP/dt,,, from 793 + 5 1 to 1343 + 75 mm Hg/s and from 825 + 38 to 2275 f 275 mm Hg/s for the 0.1-and 0.5-nmol doses, respectively. The increase in (+) dP/dt,,, for the 0.1-nmol dose did not strictly achieve statistical significance ( p = 0.09). ISP also increased (-) dP/dt,,, 
DISCUSSION
The present investigation demonstrates that PACAP produces positive inotropic and lusitropic effects in isolated neonatal pig hearts. PACAP's inotropic effect was manifested by an approximately 60% and approximately 130% increase in (+) dP/dt,,, at doses of 0.1 and 0.5 nmol, respectively. The percent changes in (+) dP/dt,,, were comparable to those produced by ISP. However, the inotropic effect of PACAP was not significantly diminished by preceptor blockade with propranolol. These results indicate that PACAP interacts with the piglet myocyte through a non-8-adrenergic receptor mediated mechanism. In support of this finding, recent investigations have demonstrated the presence of specific PACAP receptors in other tissues (18). PACAP's lusitropic effect was evident by an approximately 30% and 65% increase in (-) dP/dt,,, at the 0.1-and 0.5-nmol doses, respectively.
VIP was found to produce statistically insignificant increases in (+) and (-) dP/dt,,, when compared with PACAP. The weak inotropic effect of VIP at the doses studied is consistent with the work of Anderson ct al. (19) who showed that injections of VIP into the left coronary artery of in vivo adult dog hearts produced substantial increases in (+) dP/dt,,, only at doses in excess of approximately 0.7 nmol. However, when VIP was administered before a dose of PACAP, PACAP's effect on (+) dP/dt,,, was still significant but markedly diminished compared with the response obtained when PACAP was given in the absence of VIP (Fig. 4) . This result suggests that VIP may bind to a PACAP receptor on the myocyte to diminish PACAP's inotropic action. These findings support the speculation that PACAP and VIP may bind to a common receptor, although the mechanisms responsible for the inotropic response may differ for the two peptides. Additionally, we have found that phosphodicsterase inhibition augments PACAP's inotropic response (Fig. 5) , which is consistent with a process involving increases in intracellular levels of CAMP.
Another important finding in this study was that PACAP produces coronary vasodilation, as reflected by significant decreases in coronary perfusion pressure. The decreases in coronary perfusion pressure, observed with PACAP, were cornparablc to those produced by ISP. The vasodilatory effect of PACAP is consistent with the results of in vilro studies where PACAP produced relaxation of isolated rabbit aorta (9) and in vivo studies where PACAP was found to decrease systemic arterial blood pressure in the rat (20) . VIP produced decreases in coronary perfusion pressure that were comparable to those observed with PACAP. Coronary vasodilatory effects of VIP also have been documented by other investigators (21) . The vasodilatory responses we observed with PACAP in the coronary vasculature of the neonatal pig heart differ from the responses in the hindlimb of the cat where PACAP was found to be 3-to 10-fold less potent than VIP in dilating the hindlirnb vasculature; and both PACAP and VIP were less potent than ISP (10) . In our study, we found PACAP's coronary vasodilatory response to be at least comparable to that of ISP. The mechanism underlying the vasodilatory effect of PACAP (or VIP) on coronary vascular smooth muscle, however, has not been delineated. For example, in cerebral vessels of cats, VIP-induced vasodilation is not dependent on the release of endothelial-derived relaxing factor and is associated with increased levels of CAMP rather than cGMP (22) . To our knowledge, similar studies have not bcen conducted for PACAP. It is also possible that PACAP exerts its dilatory effect on vascular smooth muscle through inhibition of intracellular calcium release, as has been suggested for VIP (23) .
In conclusion, the present study demonstrates for the first time that PACAP, a recently discovered hypothalamic peptide structurally related to VIP, produces potent cardiac inotropic, lusitropic, and vasodilatory effects. A physiologic role for PACAP in the regulation of myocardial contractility, coronary vascular tone, or both, however, remains to be delineated. Of clinical relevance is the fact that PACAP has positive inotropic and coronary vasodilatory effects in neonatal pig hearts comparable to those of ISP. Thus, this neuropeptide may be a useful cardiotonic agent for the treatment of immature hearts with myocardial contractile dysfunction.
